Glenmark USA launches Olanzapine for Injection

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Glenmark's Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa?2 IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253].

According to IQVIA? sales data for the 12-month period ending May 2026, the Zyprexa? IntraMuscular Injection market achieved annual sales of approximately $25.4 million.